SWOG clinical trial number

S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Open

Phase

Accrual

Abbreviated Title

Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL

Status Notes

Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time

Activated

02/23/2023

Participants

ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Lymphoma

Treatment

Mosunetuzumab Polatuzumab vedotin

Patient Study Materials

Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary

Other Study Materials

S2114 Social Media Toolkit

S2114 Social Media Toolkit Graphics-JPEGS in ZIP file

Eligibility Criteria Expand/Collapse

*Please review Section 5: Eligibility of the protocol for eligibility criteria.*

Publication Information Expand/Collapse

2023

SWOG 2114: A Randomized Phase II Trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell or Grade IIIB Follicular Lymphoma

B Hess;H Li;N Hossain;V Beylergil;C Sauter;M Hamadani;J Svoboda;A Major;B Kahl;J Leonard;S Smith;M LeBlanc;P Stiff;JW Friedberg Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only

2022

A non-factorial analysis of a factorial Phase II trial design to evaluate single agent and combination consolidation therapies following CD19 CAR T-cell therapy for relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL): SWOG-S2114

H Li;M LeBlanc;B Hess;N Hossain;SM Smith;P Stiff;J Friedberg Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster

Other Clinical Trials

SWOG Clinical Trial Number

S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Research Committee(s)